Provided by Tiger Trade Technology Pte. Ltd.

Unicycive Therapeutics, Inc.

5.63
+0.18003.30%
Post-market: 5.61-0.0200-0.36%19:30 EDT
Volume:1.01M
Turnover:5.69M
Market Cap:156.83M
PE:-3.61
High:5.77
Open:5.51
Low:5.50
Close:5.45
52wk High:8.74
52wk Low:3.71
Shares:27.86M
Float Shares:25.82M
Volume Ratio:1.42
T/O Rate:3.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5585
EPS(LYR):-1.6715
ROE:-101.07%
ROA:-40.59%
PB:2.94
PE(LYR):-3.37

Loading ...

Unicycive Therapeutics Publishes Corporate Presentation on Kidney Disease Drug Pipeline

Reuters
·
Aug 01

Unicycive Therapeutics Posts Corporate Presentation on Kidney Disease Pipeline, Lead Hyperphosphatemia Drug OLC

Reuters
·
Jul 07

Unicycive Therapeutics Gets Complete Response Letter from FDA on Resubmitted Oxylanthanum Carbonate NDA

Reuters
·
Jul 06

Unicycive Therapeutics Reports Preliminary Q2 2026 Cash Position

TIPRANKS
·
Jul 02

Unicycive Therapeutics price target lowered to $13 from $18 at Benchmark

TIPRANKS
·
Jul 01

Guggenheim Remains a Buy on Unicycive Therapeutics (UNCY)

TIPRANKS
·
Jul 01

Top Midday Decliners

MT Newswires Live
·
Jul 01

Unicycive Therapeutics is Maintained at Buy by B. Riley Securities

Dow Jones
·
Jul 01

Unicycive Therapeutics price target lowered to $15 from $22 at H.C. Wainwright

TIPRANKS
·
Jul 01

Unicycive Therapeutics CRL tied to same vendor deficiency, says B. Riley

TIPRANKS
·
Jun 30

Unicycive Shares Plunge After FDA Again Rejects Oxylanthanum Carbonate

Dow Jones
·
Jun 30

Top Premarket Decliners

MT Newswires Live
·
Jun 30

U.S. Stocks on the Move-aerovironment, Oklo

Reuters
·
Jun 30

Unicycive Therapeutics Shares Down 36.9% Premarket After US FDA Declines to Approve Co's Kidney Disease Drug

THOMSON REUTERS
·
Jun 30

Unicycive Therapeutics receives complete response letter from FDA for OLD NDA

TIPRANKS
·
Jun 30

US FDA Declines to Approve Unicycive's Drug for Dialysis Patients

Reuters
·
Jun 30

Unicycive Says FDA Issues CRL for OLC NDA over Third-party Manufacturing Deficiencies

Reuters
·
Jun 30

Unicycive Therapeutics - FDA Raises no Concerns on Clinical Efficacy or Safety Data, no Additional Data Requested

THOMSON REUTERS
·
Jun 30

Unicycive Therapeutics: Remain Confident in Efficacy & Safety of Olc; Optimistic That We Will be Able to Expeditiously Resubmit Nda

THOMSON REUTERS
·
Jun 30

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (olc) New Drug Application (nda)

THOMSON REUTERS
·
Jun 30